Page last updated: 2024-08-23

amonafide and cytarabine

amonafide has been researched along with cytarabine in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Tallman, M	1
Allen, SL; Bennett, JM; Budman, DR; Capizzi, RL; Kolitz, JE; Lundberg, AS	1
Feldman, EJ	1
Allen, SL; Damon, L; Egyed, M; Erba, HP; Horst, HA; Jang, JH; Lundberg, AS; Masszi, T; Mazzola, E; Neuberg, D; Pigneux, A; Powell, B; Rizzieri, D; Sekeres, MA; Selleslag, D; Solomon, SR; Stone, RM; Stuart, RK; Tallman, MS; Venugopal, P; Warzocha, K; Wetzler, M	1

Trials

2 trial(s) available for amonafide and cytarabine

Article	Year
Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia. Leukemia research, 2010, Volume: 34, Issue:4 Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthalimides; Organophosphonates; Remission Induction; Risk Factors; Treatment Outcome; Young Adult	2010
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Apr-10, Volume: 33, Issue:11 Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Induction Chemotherapy; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthalimides; Organophosphonates; Prospective Studies; Remission Induction; Time Factors; Treatment Outcome; Young Adult	2015

Article

Year

Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia.

Leukemia research, 2010, Volume: 34, Issue:4

Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthalimides; Organophosphonates; Remission Induction; Risk Factors; Treatment Outcome; Young Adult

2010

Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Apr-10, Volume: 33, Issue:11

Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Induction Chemotherapy; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthalimides; Organophosphonates; Prospective Studies; Remission Induction; Time Factors; Treatment Outcome; Young Adult

2015

Other Studies

2 other study(ies) available for amonafide and cytarabine

Article	Year
Existing and emerging therapeutic options for the treatment of acute myeloid leukemia. Clinical advances in hematology & oncology : H&O, 2008, Volume: 6, Issue:11 Topics: Adenine; Adenine Nucleotides; Aminoglycosides; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Carbazoles; Clofarabine; Cytarabine; Dasatinib; Daunorubicin; fms-Like Tyrosine Kinase 3; Furans; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Naphthalimides; Organophosphonates; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sesquiterpenes; Staurosporine; Stem Cell Transplantation; Thiazoles; Tretinoin	2008
Does therapy-related AML have a poor prognosis, independent of the cytogenetic/molecular determinants? Best practice & research. Clinical haematology, 2011, Volume: 24, Issue:4 Topics: Adenine; Anthracyclines; Antineoplastic Agents; Biomarkers, Tumor; Cytarabine; Cytogenetics; Female; Germany; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Naphthalimides; Naphthyridines; Organophosphonates; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Thiazoles	2011

Article

Year

Existing and emerging therapeutic options for the treatment of acute myeloid leukemia.

Clinical advances in hematology & oncology : H&O, 2008, Volume: 6, Issue:11

Topics: Adenine; Adenine Nucleotides; Aminoglycosides; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Carbazoles; Clofarabine; Cytarabine; Dasatinib; Daunorubicin; fms-Like Tyrosine Kinase 3; Furans; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Naphthalimides; Organophosphonates; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sesquiterpenes; Staurosporine; Stem Cell Transplantation; Thiazoles; Tretinoin

2008

Best practice & research. Clinical haematology, 2011, Volume: 24, Issue:4

Topics: Adenine; Anthracyclines; Antineoplastic Agents; Biomarkers, Tumor; Cytarabine; Cytogenetics; Female; Germany; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Naphthalimides; Naphthyridines; Organophosphonates; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Thiazoles

2011